secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENvue Medical, Inc. (FEED)
CIK:        0001326706
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001493152-24-020229
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NanoVibronix reports record Q1 revenue of $921K; operating loss $568K
---------------------------------------------------------------------

- Q1 2024 revenue $921K, largest Q1 ever; operating loss $568K.
- Cash $2.7M, inventory $2.6M; balance sheet strong.
- GSA contract for VA sales effective May 1, 2024, expected to accelerate adoption.
- UroShield RCT study at University of Michigan begins pilot phase (up to 30 patients).
- PainShield adoption growing in VA and workers' comp markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326706/000149315224020229/0001493152-24-020229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326706/000149315224020229/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer